These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 16990777)

  • 1. Elevated levels of serum CD44 and E-cadherin predict an unfavourable outcome in myelodysplastic syndromes.
    Loeffler-Ragg J; Steurer M; Ulmer H; Skvortsov S; Kircher B; Herold M; Zwierzina H; Stauder R
    Leukemia; 2006 Nov; 20(11):2064-7. PubMed ID: 16990777
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
    Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
    Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum TNF-alpha concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes.
    Alexandrakis M; Coulocheri S; Xylouri I; Ganotakis E; Eliakis P; Karkavitsas N; Eliopoulos GD
    Haematologia (Budap); 1998; 29(1):13-24. PubMed ID: 9704253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of serum soluble E-cadherin in colorectal carcinoma.
    Okugawa Y; Toiyama Y; Inoue Y; Iwata T; Fujikawa H; Saigusa S; Konishi N; Tanaka K; Uchida K; Kusunoki M
    J Surg Res; 2012 Jun; 175(2):e67-73. PubMed ID: 22277332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep serum discoveries: SDF-1α and HSA fragments in myelodysplastic syndromes.
    Fröbel J; Hartwig S; Jourdain S; Fischer JC; Zilkens C; Kündgen A; Suckau D; Germing U; Czibere A; Lehr S
    Am J Hematol; 2015 Sep; 90(9):E185-7. PubMed ID: 26010554
    [No Abstract]   [Full Text] [Related]  

  • 6. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
    Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble CD44 isoform variant-5 (sCD44v5): a new serum marker in rheumatoid arthritis?
    Haberhauer G; Kittl EM
    J Rheumatol; 1998 Jul; 25(7):1442-4. PubMed ID: 9676786
    [No Abstract]   [Full Text] [Related]  

  • 8. Correlation between E-cadherin and CD44 adhesion molecules expression and cervical lymph node metastasis in oral tongue SCC: Predictive significance or not.
    Mostaan LV; Khorsandi MT; Sharifian SM; Shandiz FH; Mirashrafi F; Sabzari H; Badiee R; Borghei H; Yazdani N
    Pathol Res Pract; 2011 Jul; 207(7):448-51. PubMed ID: 21632186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
    Albitar M; Johnson M; Do KA; Day A; Jilani I; Pierce S; Estey E; Kantarjian H; Keating M; Verstovsek S; O'brien S; Giles FJ
    Leukemia; 2007 Mar; 21(3):480-8. PubMed ID: 17215857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Myelodysplastic syndromes. Case contributions and review of the literature].
    Pasqualetti P
    G Clin Med; 1987 May; 68(5):281-7. PubMed ID: 3622994
    [No Abstract]   [Full Text] [Related]  

  • 11. Significance of the serum level of soluble E-cadherin in patients with HCC.
    Soyama A; Eguchi S; Takatsuki M; Kawashita Y; Hidaka M; Tokai H; Nagayoshi S; Mochizuki S; Matsumoto S; Hamasaki K; Tajima Y; Kanematsu T
    Hepatogastroenterology; 2008; 55(85):1390-3. PubMed ID: 18795696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of serum E-cadherin levels in patients with haematological malignancies.
    Takubo T; Kanashima H; Terada Y; Aoyama Y; Nakamae H; Yamamura R; Shima E; Makita K; Tanaka K; Ohta K; Yamane T; Hino M; Kamitani T; Tatsumi N
    Haematologia (Budap); 2002; 31(4):319-25. PubMed ID: 12038515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence and clinical relevance of p27 and cyclin E immunoreactivity in myelodysplastic syndromes.
    Pruneri G; Fracchiolla N; Cortelezzi A; Ponzoni M; Maisonneuve P; Lambertenghi-Deliliers G
    Haematologica; 2003 Jan; 88(1):109-10. PubMed ID: 12551833
    [No Abstract]   [Full Text] [Related]  

  • 14. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
    Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
    Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative serum E-cadherin assay in patients with ovarian carcinoma.
    Gadducci A; Ferdeghini M; Cosio S; Annicchiarico C; Ciampi B; Bianchi R; Genazzani AR
    Anticancer Res; 1999; 19(1B):769-72. PubMed ID: 10216491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunophenotypic characterization of myelopoiesis in early and late myelodysplastic syndromes: use of CD44 as an aid in early diagnosis.
    Karmon Y; Manaster J; Chezar J
    Cytometry; 2002 Aug; 50(4):225-30. PubMed ID: 12210602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin.
    Chan AO; Chu KM; Lam SK; Cheung KL; Law S; Kwok KF; Wong WM; Yuen MF; Wong BC
    Cancer; 2005 Aug; 104(4):740-6. PubMed ID: 15991243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes of the complement system in myelodysplastic syndromes].
    Villaescusa Blanco R; Arce AA; Santos RM; Fernández N
    Sangre (Barc); 1998 Jun; 43(3):210-2. PubMed ID: 9741227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are serum levels of CD44 relevant in children with pediatric sarcomas?
    Kebudi R; Ayan I; Yasasever V; Demokan S; Görgün O
    Pediatr Blood Cancer; 2006 Jan; 46(1):62-5. PubMed ID: 16155927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myelodysplastic syndromes: characterization of a series of 56 patients classified according to FAB criteria].
    del Cañizo MC; San Miguel JF; Gascón A; Rios A; Moraleda JM; González M; Anta JP; Sánchez J; López Borrasca A
    Sangre (Barc); 1987; 32(4):436-44. PubMed ID: 3660181
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.